Anti-CEP290 [1C3G10]

CEP290 is involved in early and late steps in cilia formation. Its association with CCP110 is required for inhibition of primary cilia formation by CCP110 (PubMed:18694559).

Contributors

Inventor Institute
Ciaran Morrison National University of Ireland, Galway ; Centre For Chromosome Biology
Cat. #: 153781
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Cancer;Cell biology;Metabolism
Application: IHC ; IF ; WB
Target: CEP290, UniProt ID:O15078
Reactivity: Human
Clone: [1C3G10]
Host: Mouse
Class: Monoclonal
Alternate name: Centrosomal protein of 29 kDa, Cep29, Bardet-Biedl syndrome 14 protein, Cancer/testis antigen 87, CT87, Nephrocystin-6, Tumor antigen se2-2
Product description: CEP290 is involved in early and late steps in cilia formation. Its association with CCP110 is required for inhibition of primary cilia formation by CCP110 (PubMed:18694559). May play a role in early ciliogenesis in the disappearance of centriolar satellites and in the transition of primary ciliar vesicles (PCVs) to capped ciliary vesicles (CCVs). Required for the centrosomal recruitment of RAB8A and for the targeting of centriole satellite proteins to centrosomes such as of PCM1 (PubMed:24421332). Required for the correct localization of ciliary and phototransduction proteins in retinal photoreceptor cells; may play a role in ciliary transport processes (By similarity). Required for efficient recruitment of RAB8A to primary cilium (PubMed:17705300). In the ciliary transition zone is part of the tectonic-like complex which is required for tissue-specific ciliogenesis and may regulate ciliary membrane composition (By similarity). Involved in regulation of the BBSome complex integrity, specifically for presence of BBS2, BBS5 and BBS8/TTC8 in the complex, and in ciliary targeting of selected BBSome cargos. May play a role in controlling entry of the BBSome complex to cilia possibly implicating IQCB1/NPHP5 (PubMed:25552655). Activates ATF4-mediated transcription (PubMed:16682973).
Conjugation: Unconjugated
Isotype: IgG2a
Molecular weight: 290 kDa
Immunogen: Recombinant human CEP290 amino acids 1-299 (bacterially expressed from pGEX4T as a GST fusion, then thrombin-cleaved and purified).
Myeloma used: Sp2/0-Ag14
Target background: CEP290 is involved in early and late steps in cilia formation. Its association with CCP110 is required for inhibition of primary cilia formation by CCP110 (PubMed:18694559). May play a role in early ciliogenesis in the disappearance of centriolar satellites and in the transition of primary ciliar vesicles (PCVs) to capped ciliary vesicles (CCVs). Required for the centrosomal recruitment of RAB8A and for the targeting of centriole satellite proteins to centrosomes such as of PCM1 (PubMed:24421332). Required for the correct localization of ciliary and phototransduction proteins in retinal photoreceptor cells; may play a role in ciliary transport processes (By similarity). Required for efficient recruitment of RAB8A to primary cilium (PubMed:17705300). In the ciliary transition zone is part of the tectonic-like complex which is required for tissue-specific ciliogenesis and may regulate ciliary membrane composition (By similarity). Involved in regulation of the BBSome complex integrity, specifically for presence of BBS2, BBS5 and BBS8/TTC8 in the complex, and in ciliary targeting of selected BBSome cargos. May play a role in controlling entry of the BBSome complex to cilia possibly implicating IQCB1/NPHP5 (PubMed:25552655). Activates ATF4-mediated transcription (PubMed:16682973).
Format: Liquid
Concentration: 0.9-1.1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Mercey et al. 2022. PLoS Biol. 20(6):e3001649. PMID: 35709082.

Related Tools for Antibodies

Cat. # Tool Name
151030 Anti-Progesterone [11P14] Key Info View Tool
151022 Anti-IL12 [1-1A4] Key Info View Tool
151038 Anti-Cytochrome P450 4A2, 4A3 [Clo4] Key Info View Tool
151039 Anti-Integrin aVb3 [23C6] Key Info View Tool
151040 Anti-CD11 & CD18 [24] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.